

From Efficacy to Equity in Rare Disorders: Clinical and Policy Decisionmaking on Growth Hormone for Patients with Prader-Willi Syndrome Using the EVIDEM HTA Web Model

Michèle Tony MSc,^{1,2,3} Mireille M. Goetghebeur PhD,^{2,3,4} Hanane Khoury PhD,³ Monika Wagner PhD,³ Renaldo Battista MD, ScD,^{1,4}

Cheri L. Deal PhD, MD^{4,5}

¹Health Administration, Medical Faculty, University of Montreal, Montréal, Québec, Canada; ²EVIDEM Collaboration, Dorval, Québec, Canada; ³BioMedCom Consultants inc., Dorval, Québec, Canada; ⁴Research Center, CHU-Sainte-Justine and ⁵Department of Pediatrics, Medical Faculty, University of Montreal, Montréal, Québec, Canada

Background & Objective

- Healthcare decisionmaking is a complex process that requires consideration of a wide range of scientific and contextual criteria and inherently involves value judgments.¹
- At the policy level, this process demands transparency, consistency, and accountability to be perceived as legitimate and to increase the likelihood of making good decisions.^{2,3} At the clinical level, development of recommendations to guide clinical practice also requires consideration of a broad range of aspects to ensure optimal care^{4,5} and social responsibility.
- The EVIDEM framework is a systematic approach to synthesize and consider evidence by decision criteria.^{6,7} It could provide a consistent structure to organize evidence and facilitate both clinical and policy making by supporting respectively clinical practice guidelines (CPGs) development and health technology assessment (HTA).
- Prader-Willi syndrome (PWS) is a rare and complex multisystem disorder, with serious long-term consequences. Use and coverage of growth hormone (GH) in patients with PWS vary widely across Canada and there is a need to clarify its benefits.
- Objective: Develop a comprehensive web-based validated EVIDEM HTA report to facilitate the development of CPGs and policy recommendations for rare disorders.

Methodology

- An extensive literature review was performed to identify available evidence on GH for PWS for each criterion of the framework covering disease impact, therapeutic context, treatment outcomes (efficacy/effectiveness, safety, patient-reported outcomes), type of benefits and economic impact (MCDA Core Model) as well as ethical and contextual considerations (Contextual Tool).
- Given the complexity of the efficacy outcomes measures reported, the efficacy criterion was subdivided into sub-criteria for each type of outcome measured including growth, body composition, exercise tolerance, metabolic effects, bone health, cardiovascular health, psychomotor development and behavioral outcomes.
- Data was organized in evidence tables and synthesized; level and strength of evidence were assessed using respectively the Centre for Evidence-Based Medicine (CEBM) levels of evidence⁸ and EVIDEM data quality assessment instruments.
- To support the development of recommendations, the framework was used to elicit questions and an interactive web information system was developed to facilitate the processes.

Key Steps for Development of Clinical and Policy Recommendations Using EVIDEM



Results

- Based on the analysis of the literature and feedback from experts, questions reflecting current issues in management of patients PWS were developed and organized using the adapted EVIDEM framework (Intervention & Overview, MCDA Core Model and Contextual Tool).
- This framework structure and questions identified will be used sequentially to:
 - Structure a consensus workshop and assign questions to CPGs working groups to develop CPGs guidelines.
 - Structure deliberations of a pan-Canadian taskforce to examine the conditions for successful implementation (obstacles and facilitating factors) of evidence-based CPGs.

Clinical Aspects

Intervention Overview

- Do patients with PWS need GH testing: In infancy? In childhood? In adulthood?
- What baseline evaluations need to be performed before GH treatment?
- Intervention duration:
 - For how long should GH therapy be pursued?
 - What clinical lab tests or imaging studies need to be done to monitor treatment?
 - What doses should be used for GH therapy: In infants? In children and adolescents? In adults?
 - Is there an optimal level of circulating IGF-1 to obtain with GH treatment?
 - Should GH doses be titrated to IGF-1, and if so, at what frequency?
 - What is the frequency of follow-up visits necessary to adequately monitor GH therapy?
- Comparator(s):
 - What other therapeutic interventions have been tried in PWS?

MCDA Core Model

Decision Criteria	Proposed questions
D1 - Disease severity	10. What is the frequency of the various genetic subtypes among various populations? 11. How has evolution of our genetic testing methodology changed genetic subtype frequency? 12. Are all patients with PWS equally GH deficient? 13. Are there genotype/phenotype correlations relevant to specific to clinical outcome measures targeted with GH therapy? Other correlations? 14. What are the important co-morbidities that need to be considered when considering GH therapy? 15. What is the life expectancy of PWS subjects? 16. What are the major causes of death in PWS subjects? 17. What is the birth incidence/prevalence of PWS?
D2 - Size of population	18. Why are physicians divided in their belief about the benefits of GH therapy?
Therapeutic context of intervention	19. For each of the other therapies/interventions tried in PWS, what were the specific outcomes? The efficacy per outcome? The safety/tolerability of the therapy/intervention? 20. What specific therapies/interventions have been tried concomitant to GH therapy? 21. What are the nutritional recommendations for infants with PWS? Children with PWS? Adolescents with PWS? Adults with PWS?
Intervention outcomes	22. What are the most important clinical outcome priorities when initiating GH therapy in subjects with PWS: In infancy? In childhood? In adolescence? In Adulthood? 23. What is the best way to measure GH effectiveness on: a. Growth b. Body composition c. Motor development (infants and children) d. Neurological status e. Physical activity f. Muscle strength 24. What is the impact of other hormonal deficiencies on GH treatment? 25. Does response to GH vary by: a. age at start of treatment b. dose c. body composition at start d. degree of dietary control e. level of physical activity 26. What are the major serious adverse events of GH treatment of PWS subjects? 27. What is the evidence that GH treatment in PWS increases the risk of: a. Sleep apnea b. Sudden death c. Scoliosis d. Diabetes e. Intracranial hypertension f. Epilepsy g. Slipped capital femoral epiphyses h. Osteoarthritis/cranial bleeding 28. What is the tolerability of GH: In published clinical trials (dropouts rate)? In patient-reported data? In 4 trials? In smaller observational studies? 29. What are the main reasons given for patient withdrawal from clinical trials of GH in PWS? 30. What are the most significant benefits reported by patients and/or parents after GH treatment?
I1 - Improvement of efficiency/effectiveness	
I2 - Improvement of safety & tolerability	

MCDA Core Model (continued)

Decision Criteria	Proposed Questions
Type of benefits	31. Is there any risk reduction associated with GH treatment in patients with PWS?
T2 - Type of medical service (eg. work, recreation)	32. What are the least important, but significant, clinical outcomes to GH therapy? 33. What known GH effects have not been adequately studied in PWS?
Quality/uncertainty of evidence	34. What are the confounding variables that are difficult to control in PWS GH clinical trials? 35. What is the best way to report efficacy data according to current recommendations, and why? 36. Is there a place for a therapeutic trial of GH, and if so, how long before assessing GH effectiveness? 37. When sources of potential study bias are considered (adequate randomization and blinding of patients and health professionals, adequate description of withdrawals and dropouts, provision of intention-to-treat analysis), what proportion of the clinical trials have a high risk of bias, ie, one or more of the previous criteria not met? 38. What questions with regards to GH use in PWS require further study? 39. What are the major research areas with regards to PWS that need to be addressed beyond issues of GH use?

Resource Allocation and Ethical Aspects Overview

- Economic burden of illness:**
40. What are the major sources of healthcare costs related to the care of patients with PWS?
 41. What are the major costs of treating morbid obesity?
 42. What are the major costs of treating diabetes?

MCDA Core Model (continued)

Decision Criteria	Proposed Questions
Economic of intervention	43. What is the cost of GH treatment in patients with PWS? impact on health 44. What is the budget impact at the country level?
E2 - Cost-effectiveness of intervention	45. What is the cost-effectiveness of GH treatment in patients with PWS?
E3 - Impact on other spending (eg. transportation, disability)	46. What are the economic consequences (beyond drug costs) of GH treatment in patients with PWS?

Contextual Tool

Decision Criteria	Proposed Questions
Ethical criteria	47. Is the use of GH in patients with PWS aligned with the mission and scope of healthcare systems? 48. How do we prioritize resources for PWS care, and how does GH fit into this? 49. Is access to GH therapy available to all PWS patients, and if not, why? 50. Are there issues of fairness in withholding GH treatment, or in targeting specific sub-populations of PWS subjects for GH therapy?
Other context	51. How do we organize the comprehensive care of the PWS patient, to optimize GH treatment and particularly to decrease/prevent potential side effects? 52. What are the evidence-based steps that are needed to harmonize care of patients with PWS? 53. Are there any pressures/barriers for the use of GH in patients with PWS? 54. Are there any specific political/historical context impacting the use of GH in patients with PWS?

Collaborative Web Site

- A collaborative web site was built to facilitate the process including:
 - Access to evidence and questions structured in a consistent systematic manner
 - Interactive online validation by international experts of: synthesized data; quality assessments of evidence; and questions
 - Involvement of all stakeholders prior to the workshops
- To facilitate knowledge transfer, validated synthesized data on GH for PWS, CPGs and taskforce recommendations, and the process to develop them, will be made publicly available under a Creative Commons license.⁹

Discussion and Conclusion

- Questions elicitation and organization was facilitated by the EVIDEM framework, providing a pragmatic means to ensure systematic consideration of evidence for a wide range of criteria and associated issues.
- By clearly revealing current knowledge and gaps, the framework will facilitate developing evidence-based CPGs and policy recommendations as well as identifying research needed for continued improvement of management of patient with PWS.
- This comprehensive by-criteria approach in synthesizing and defining questions provides a common road map to streamline clinical and policy decisionmaking to optimize resource allocation and healthcare system sustainability.
- The ultimate goal is to bridge the gap between researchers, HTA, policy decisionmaking, clinical practice and patient concerns.

Acknowledgments

We would like to acknowledge the contributions of the members of the CPGs workshop organizing committee who participated in this study. The consensus workshop is sponsored by the Growth Hormone Research Society and a complementary grant from the Foundation for Prader-Willi Research. Internal sources of support were provided by BioMedCom Consultants, Inc. Web development was supported by the EVIDEM Collaboration.

References

- Baltussen R, Niessen L. Priority setting of health interventions: the need for multi-criteria decision analysis. *Cost Eff Resour Alloc* 2006;4:14-2. Daniels N, Sabin J. Limits to health care: fair procedures, democratic deliberation, and the legitimacy problem for insurers. *Philos Public Aff*. 1997;26(4):303-50. 3. Dhalla I, Laupacis A. Moving from opacity to transparency in pharmaceutical policy. *CMAJ*. 2008;178(4):428-31. 4. Brouwers MC, Kho ME, Browman GP, Burgers JS, Cuzouai F, Feder G, et al. AGREE II: advancing guideline development, reporting, and evaluation in health care. *Prev Med*. 2010;51(5):421-4. 5. AGREE Collaboration. Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: the AGREE project. *Qual Saf Health Care*. 2003;12(1):18-23. 6. Goetghebeur MM, Wagner M, Khoury H, Levitt RJ, Erickson LJ, Rindress D. Evidence and Value: Impact of DecisionMaking - the EVIDEM framework and potential applications. *BMC Health Serv Res*. 2008;8(1):270. 7. Goetghebeur MM, Wagner M, Khoury H, Rindress D, Gregoire JP, Deal C. Combining multicriteria decision analysis, ethics and health technology assessment: applying the EVIDEM decisionmaking framework to growth hormone for Turner syndrome patients. *Cost Eff Resour Alloc*. 2010;8(1):4. 8. Centre for Evidence Based Medicine. CEBM levels of evidence version #2. On Centre for Evidence Based Medicine website. Available from: <http://www.cebm.net/index.aspx?o=5653.9>. EVIDEM Collaboration. Open access prototypes of the Collaborative registry. On EVIDEM Collaboration website. Available from: <http://www.evidem.org/evidem-collaborative.php>.

